Bio-Rad Laboratories (NYSE:BIO – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.
Earnings and Valuation
This table compares Bio-Rad Laboratories and Champions Oncology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Rad Laboratories | $2.58 billion | 3.80 | $759.90 million | $8.25 | 44.46 |
| Champions Oncology | $59.42 million | 1.16 | -$1.17 million | ($0.08) | -61.70 |
Risk & Volatility
Bio-Rad Laboratories has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.
Profitability
This table compares Bio-Rad Laboratories and Champions Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Rad Laboratories | 8.59% | 3.54% | 2.48% |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Bio-Rad Laboratories and Champions Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Rad Laboratories | 0 | 4 | 1 | 0 | 2.20 |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
Bio-Rad Laboratories presently has a consensus price target of $343.33, suggesting a potential downside of 6.40%. Given Bio-Rad Laboratories’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Bio-Rad Laboratories is more favorable than Champions Oncology.
Institutional & Insider Ownership
65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 46.3% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Bio-Rad Laboratories beats Champions Oncology on 13 of the 14 factors compared between the two stocks.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
